MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Inclusion Criteria

• •Meets ONE of the following disease criteria:
• •1. Primary AML induction failure: no CR after 2 or more induction attempts
• •2. Relapsed AML or Secondary AML (from MDS or treatment related): not in CR after 1 or more cycles of standard re-induction therapy
• •3. AML relapsed \> 2 months after transplant: No re-induction required, and no more than 1 re-induction cycle is allowed.
• •4. Relapsed AML for patients \> 60 years of age the 1 cycle of standard chemotherapy is not required if either of the following criteria is met:
• •* Relapse within 6 months of last chemotherapy
• •* BM blast count \< 30% within 10 days of starting protocol therapy
• •Available related HLA-haploidentical donor (aged 14 to 75 years) by at least Class I serologic typing at the A\&B locus
• •Karnofsky Performance Status ≥ 60%
• •Patients must have adequate organ within 14 days (28 days for pulmonary and cardiac) of study registration
• •Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to NK cell infusion (excluding preparative regimen pre-medications).
• •Agrees to use contraception prior to study entry and for the duration of study participation.